RxDoctor Payments Data

Heather Poppell, APRN

Family · Ocala, FLNPI 1184281057

Payments from drug & device makers

$8,472in general payments, 2019–2025

Across 369 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$974
  • Merck$720
  • Theratechnologies Inc.$627
  • Averitas Pharma Inc.$593
  • Aimmune Therapeutics, Inc.$519
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,445100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,472 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$5,861
Medicare patients
42
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala108$468,212
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf30$162,638
RukobiaFostemsavir Tromethamine12$105,957
JulucaDolutegravir/Rilpivirine16$62,689
IsentressRaltegravir Potassium22$45,931
PrezcobixDarunavir/Cobicistat14$39,115
DescovyEmtricitabine/Tenofov Alafenam14$30,277
PifeltroDoravirine14$27,884
Vancomycin Hcl72$20,490
Daptomycin22$13,672
ErtapenemErtapenem Sodium12$12,549
Tenofovir Disoproxil Fumarate14$8,955
CeftriaxoneCeftriaxone Sodium34$8,302
SantylCollagenase Clostridium Hist.17$7,682
Cefepime Hcl33$4,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,743$498,489122 claims
Viiv Healthcare CompanyRukobia, Juluca$974$168,64628 claims
MerckIsentress, Pifeltro$720$73,81636 claims
Johnson & JohnsonPrezcobix$491$39,11514 claims
Smith+NephewSantyl$183$7,68217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →